Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Liabilities and Shareholders Equity (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $252.3 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 35.81% to $252.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, down 29.51% year-over-year, with the annual reading at $252.3 million for FY2025, 35.81% down from the prior year.
  • Liabilities and Shareholders Equity hit $252.3 million in Q4 2025 for Voyager Therapeutics, down from $288.3 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $469.6 million in Q1 2024 to a low of $159.4 million in Q4 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $290.9 million across 5 years, with a median of $291.5 million in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 120.44% in 2023 and later crashed 35.81% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $193.9 million in 2021, then fell by 17.8% to $159.4 million in 2022, then soared by 120.44% to $351.3 million in 2023, then rose by 11.89% to $393.0 million in 2024, then plummeted by 35.81% to $252.3 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for VYGR at $252.3 million in Q4 2025, $288.3 million in Q3 2025, and $322.1 million in Q2 2025.